A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes

Autori: Lambiase S., Cavalloro D., Cioni A., Matteini E., Artosi F., Poscente F., Belardi R., Terrinoni A., Bernardini S., Bianchi L.

A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes. Journal of Clinical Medicine, 2025. DOI: 10.3390/jcm14228170